Other studies have demonstrated that differences in rates of IPV among women can be largely explained by socioeconomic variables [41, 42]. However, it is important to acknowledge that ethnicity

may shape a woman’s experience of IPV, including her willingness to disclose and seek help [43]. There were several limitations to our study. Our ability to infer causality is limited by the cross-sectional design. We also recognize that the small sample size limited our power to detect true associations between IPV and other variables. There is likely to have been selection bias, but it is difficult to predict whether women who NVP-BKM120 research buy had experienced IPV would have been more or less likely to participate. We excluded 16 women with severe mental health problems and we were not able to recruit any IDUs, which suggests that we may have underestimated

the prevalence of IPV in our population. Furthermore, 110 women (25%) were not approached by clinic staff to participate in the study. This may have been a consequence of various factors including lack of time or other more pressing matters such as ill health. In some cases it may have been because the staff member did not feel it was appropriate to ask them to participate, which may contribute to selection bias. However, we do not feel this was a dominant factor. Belnacasan price When comparing the 191 women who participated in this study with all women attending the clinic in 2011, we found the women in the study to be broadly similar in terms of age, ethnicity, acquisition risk and CD4 count. This suggests that our sample was representative of the clinic population. A final limitation is that our outcome measure was based on self-defined

lifetime experience of IPV. We cannot exclude the possibility that women answered incorrectly because of either poor recall or social desirability. The majority of the women in our study, regardless of their experience of IPV, wanted their clinic doctor to receive a copy of their completed questionnaire. This suggests that screening Isotretinoin within our clinical setting would be acceptable. Previous research based in general practice and secondary care in the UK has demonstrated that enquiring about IPV is generally acceptable to women [44]. Another recent study found that abused women wanted their GP to enquire about IPV; however, they wished to then be referred on to specialized advocacy services [45]. The high prevalence of IPV in women in this study suggests that HIV clinics should screen routinely for IPV. The relative lack of associated factors that could identify those at risk suggests that screening should be universal. Although other UK centres may have a smaller proportion of female patients, our sample is likely to be representative of women attending for HIV care in the UK and our findings can be generalized.